Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-24T06:35:01.941Z Has data issue: false hasContentIssue false

Chlorpromazine Metabolism in Chronic Schizophrenics

Published online by Cambridge University Press:  29 January 2018

S. Sved
Affiliation:
Institut de Recherches Psychiatriques de Joliette, 1000, boul Ste-Anne, Joliette, Quebec, Canada
A. Perales
Affiliation:
Los Cedros 202, Res. San Felipe, Lima 11, Peru
D. Palaic
Affiliation:
Institut de Recherches Psychiatriques de Joliette, 1000, boul. Ste-Anne, Joliette, Quebec, Canada

Extract

At present the phenothiazine drugs constitute the medication of choice in the treatment of schizophrenia. While in most schizophrenics treatment with phenothiazines does ameliorate the symptoms of the disease there are a certain number of patients who remain resistant to therapy. In such patients the side effects caused by phenothiazines may also be less pronounced or completely absent.

Type
Research Article
Copyright
Copyright © Royal College of Psychiatrists, 1971 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Barsa, J. A., Newton, J. C., and Saunders, J. C. (1965). ‘Lenticular and corneal opacities during phenothiazine therapy.’ Journal of the American Medical Association, 193, 1012.Google Scholar
2. Cole, J. O., and Davis, J. M. (1969). ‘Antipsychotic drugs.’ In The Schizophrenic Syndrome (ed. Bellak, L. and Loeb, L.). New York: Grune and Stratton.Google Scholar
3. Cowen, M. A., and Martin, W. C. (1968). ‘Long-term chlorpromazine retention and its modification by steroids.’ American Journal of Psychiatry, 125, 243–45.CrossRefGoogle ScholarPubMed
4. Curry, S. H. (1968). ‘Method for the estimation of nanogram quantities of chlorpromazine and some of its relatively non-polar metabolites in plasma using gas-chromatography with an electron capture detector.’ Analytical Chemistry, 40, 1251–56.CrossRefGoogle Scholar
5. Forrest, I. S., Bolt, A. G., and Serra, M. T. (1968). ‘Distribution of chlorpromazine metabolites in selected organs of psychiatric patients chronically dosed up to the time of death.’ Biochemical Pharmacology, 17, 2061–70.CrossRefGoogle Scholar
6. Hollister, L. E. (1964). ‘Adverse reactions to phenothiazines.’ Journal of the American Medical Association, 189, 311–13.Google ScholarPubMed
7. Klein, D. F. (1967). ‘Importance of psychiatric diagnosis in prediction of clinical drug effects.’ Archives Générales de Psychiatrie, 16, 118–26.Google Scholar
8. Lutz, E. G. (1965). ‘Dissipation of phenothiazine effect and recurrence of schizophrenic psychosis.’ Diseases of the Nervous System, 26, 355–57.Google Scholar
9. Mellinger, T. J., and Keeler, C. E. (1963). ‘Spectrofluorometric identification of phenothiazine drugs.’ Analytical Chemistry, 35, 554–8.Google Scholar
10. Mellinger, T. J., and Keeler, C. E. (1964). ‘Factors influencing spectrofluorometry of phenothiazine drugs.’ Analytical Chemistry, 36, 1840–47.CrossRefGoogle Scholar
11. Polatin, P. (1966). In A Guide to Treatment in Psychiatry (ed. J. B. Lippincott Co.). Philadelphia, pp. 218–9.Google Scholar
12. Simpson, G. M., Amin, M., and Kunz, E. (1965). ‘Withdrawal effects of phenothiazines.’ Comprehensive Psychiatry, 6, 347–51.Google Scholar
13. Sved, S. (1969). ‘The column chromatography of chlorpromazine and its metabolites in urine.’ Clinical Biochemistry, 2, 369–72.Google Scholar
14. Technicon AutoAnalyzer Methodology (1963). Creatinine, N-lla. Form 350-11-2 R 6-3.Google Scholar
15. Woods, L. A. (1954). ‘Distribution and fate of morphine in non-tolerant and tolerant dogs and rats.’ Journal of Pharmacology and Experimental Therapeutics, 112, 158–75.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.